Based on the terms of the agreement, BridgeBio will receive a $30 million milestone payment upon approval in Japan, as well ...

Genetic diseases company BridgeBio Pharma has announced that the Japanese Ministry of Health, Labor and Welfare has approved ...

In the Japanese Phase 3 study, 0% mortality was reported over the 30-month treatment period and acoramidis was well-tolerated ...

Alexion has been working hard to flesh out is pipeline as well, snapping up Achillion Pharma, Syntimmune, Wilson Therapeutics and Portola and forging an alliance with gene-silencing specialist ...

head of Alexion’s new development hub, about these new ventures and about why and how big pharma tackles small diseases. Novo’s name change Novo Nordisk is far from new to the world of rare di ...

BridgeBio Pharma (BBIO) announced the Japanese Ministry of Health, Labour and Welfare, MHLW, has approved acoramidis, under the brand name ...

The healthcare and fitness wearables landscape is transforming rapidly, with tech giants investing heavily to improve the ...

Argenx is a hold due to limited catalysts in 2025, a rich valuation and clinical risk around label expansion. Read more about ...

Rheumatologists and cardiologists have long co-managed patients out of necessity and without much formal collaboration or ...

Mar. 18, 2025 — A research team has found that lecanemab was probably less effective in females than males in its Phase 3 trial. However, there was insufficient evidence to say the drug was ...

Healthcare & Pharmaceuticalscategory· March 21, 2025 Alnylam jumps as expanded US approval for heart disease drug fuels growth prospects Alnylam Pharmaceuticals' shares rose more than 10% on ...

Rumeysa Ozturk's supporters say her detention is the first known immigration arrest of a Boston-area student involved in pro-Palestinian protests to be carried out by Trump's administration. US ...